All hepatitis C patients treated with Gilead Sciences' GS-7977 plus Bristol-Myers Squibb's daclatasvir attained a sustained virologic response four weeks after the treatment, a clinical trial found. In another study, 88% of 25 treatment-naive patients with genotype 1 hepatitis C who received Gilead's GS-7977 and ribavirin achieved SVR 4 after 12 weeks of treatment. The results boost the possibilities for an interferon-free, all-oral regimen for hepatitis C.